McWilliams, R. R., Foster, N. R., Mahoney, M. R., Smyrk, T. C., Murray, J. A., Ames, M. M., . . . Goetz, M. P. (2017). NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma. Cancer.
Chicago ZitierstilMcWilliams, Robert R., et al. "NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine As First-Line Therapy for Advanced Small Bowel Adenocarcinoma." Cancer 2017.
MLA ZitierstilMcWilliams, Robert R., et al. "NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine As First-Line Therapy for Advanced Small Bowel Adenocarcinoma." Cancer 2017.